MedTrace Logo

Predictive Value of Analysing Tissue From Patients With Metastatic Pancreatic Cancer for Drug Sensitivity

NCT03821870 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2023-05-01

No results posted yet for this study

Summary

It will be investigated whether it is possible to predict the effect or lack of effect of first-line treatment by analysing cancer cells from the individual patient receiving standard first line treatment. Also, the feasibility of selecting second-line therapy based on pre-treatment biopsies will be investigated.

Cells from pancreatic cancer will be grown in the laboratory to form small, circulating tumors and adjacent tissue, so called tumoroids. The tumoroids will then be exposed to different pre-specified anticancer drugs to hopefully reveal sensitivity or lack of sensitivity in the specific patient.

Conditions

Interventions

DIAGNOSTIC_TEST

Inditreat

Tumoroid formation and drug sensitivity analysis

DRUG

Experimental drug

Second line treatment based on drug sensitivity analysis

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Principal Investigators

  • Lars Henrik Jensen, MD, PhD · Vejle Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-25
Primary Completion
2021-12-31
Completion
2023-02-22

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03821870 on ClinicalTrials.gov